Abstract: An optical component includes a substrate and two optical lenses, and the substrate and the two optical lenses are an integrated and inseparable structure. A groove that can accommodate a required collimating optical element is provided on the substrate, or a collimating optical element and the substrate are integrated. Because fabrication of optical elements is completed during fabrication of the optical component, the number of elements to fabricate and time and cost of fabricating the elements can be reduced. Also, during assembly of an image capturing device, it is only required that the optical component is locked to a body of the image capturing device to complete arrangement of a front panel and the optical elements, which can greatly simplify an assembly procedure and shorten assembly time.

Abstract: The invention provides novel immunogenic proteins LigA and LigB from Leptospira for use in the development of effective vaccines and antibodies, as well as improved diagnostic methods and kits.

Abstract: An optical electrical device comprises a base and a transparent conductive structure on the base is disclosed. The base further comprises a light-emitting device and the transparent conductive structure comprises a transparent conductive oxide layer and a passivation layer on the transparent conductive oxide layer. The material of the transparent conductive oxide layer comprises transparent conductive metal oxide, such as ZnO. Furthermore, the transparent conductive metal oxide also comprises impurities, such as a carrier e.g. gallium.

Abstract: The invention provides novel immunogenic proteins LigA and LigB from Leptospira for use in the development of effective vaccines and antibodies, as well as improved diagnostic methods and kits.

Abstract: A nucleic acid construct comprising a genetic engineered heterogeneous nuclear ribonucleoprotein (hnRNP) A1 gene is provided. A transgenic mouse in which the expression of hnRNP A1 gene has been disrupted is also provided. The mouse is useful for studying the role of hnRNP A1 gene in normal and disease states of a developmental disorder and muscular diseases. Therefore, a method of screening a compound for potential use in prevention and/or treatment of developmental disorder and muscular diseases is further provided.

Abstract: A nucleic acid construct comprising a genetic engineered heterogeneous nuclear ribonucleoprotein (hnRNP) A1 gene is provided. A transgenic mouse in which the expression of hnRNP A1 gene has been disrupted is also provided. The mouse is useful for studying the role of hnRNP A1 gene in normal and disease states of a neurodegenerative disease or a cancer for developing therapies to treat any of these diseases. Therefore, a method of screening a compound for potential use in prevention and/or treatment of neurodegenerative disease or cancer is further provided.

Abstract: Embodiments of the invention provide a system and method for automatically managing a network port based on a calendar function. In one embodiment, a discovery protocol is provided for automatically discovering at least one port of at least one switch in a network. Furthermore, a management protocol is provided. The management protocol is configured to automatically manage the at least one port of the at least one switch in the network based on a programmable calendar function. In addition, a reconfiguration protocol is also provided. The reconfiguration protocol is configured to reconfigure the calendar function of the automatic management of the at least one port of the at least one switch in the network.

Abstract: The invention provides novel immunogenic proteins LigA and LigB from Leptospira for use in the development of effective vaccines and antibodies, as well as improved diagnostic methods and kits.

Abstract: Leptospira outer membrane proteins (OMPs) LP1454, LP1118, LP1939, MCEII, CADF-like1, CADF-like2, CADF-like3, Lp0022, Lp1499, Lp4337, Lp328 or L21 are provided. The OMPS can be used as tools for developing effective vaccines or diagnostic methods for leptospirosis. Expression vectors for the OMP genes are further provided. The antigenic properties of the Leptospira OMPs can be used to create, manufacture or improve vaccines. Vaccines, including but not limited to DNA vaccines, recombinant vaccines, and T-cell epitope vaccines based on the foregoing OMPs are also provided. Methods for producing such vaccines are also provided. Also provided are methods for using Leptospira OMP genes, proteins and antibodies for therapeutic treatment and serological diagnosis techniques.

Abstract: This invention provides the sequence of 5,299 nucleotides from the E. canis genome. There are four proteins, ProA, ProB, MmpA, and a cytochrome oxidase homolog, as well as a partial lipoprotein signal peptidase homolog at the carboxy terminus, coded for in this cloned fragment. The antigenic properties of these proteins allow them to be used to create a vaccine. An embodiment of this invention includes the creation of a DNA vaccine, a recombinant vaccine, and a T cell epitope vaccine. Another embodiment of this invention includes the use of serological diagnosis techniques.

Abstract: The invention provides novel immunogenic proteins LigA and LigB from Leptospira for use in the development of effective vaccines and antibodies, as well as improved diagnostic methods and kits.

Abstract: The invention provides compositions and method for stimulating an immunological response against Mycobacterium avium subspecies paratuberculosis (MPT). The compositions comprise at least five recombinant immunogenic components. The immunogenic components can be MPT antigens or DNA polynucleotides encoding MPT antigens, or combinations thereof. MPT antigens used in the invention include MPT 85A, 85B, 85C, 35 kDa, super oxide dismutase (SOD), MptC, MptD and ESAT-6 protein. The method comprises administering the composition to an animal in an amount effective to stimulate an immunological response against MPT bacteria. The method is of benefit to any animal susceptible to MPT infection, but is particularly beneficial for ruminants.

Abstract: An array is formed with a protective cover on a substrate. The protective cover is patterned to produce an array of openings to the substrate. Desired material is deposited on the substrate through the openings. The protective cover may then be removed. In one embodiment, the protective cover is a conformal polymer, such as di-para-xylylene. It may be removed by mechanical peeling. The material may be biological material such as DNA. The protective cover may be used to prevent non-specific hybridization in inter-spot regions by performing hybridization with the cover still in place. Hybridization that occurs in such regions between the spots may be removed with removal of the protective cover.

Abstract: Provided are compositions and methods for stimulating an immune response against Mycobacterium avium subspecies paratuberculosis (MAP). The compositions include a recombinant polypeptide that contains from its N-terminus to C-terminus a C-terminal fragment of MAP protein Map3527, a Map1519 protein amino acid sequence, followed by an N-terminal portion of Map3527. The method comprises administering the composition to an animal in an amount effective to stimulate an immunological response against MAP bacteria. The method is of benefit to any animal susceptible to MAP infection, but is particularly beneficial for ruminants.

Abstract: The invention provides compositions and method for stimulating an immunological response against Mycobacterium avium subspecies paratuberculosis (MPT). The compositions comprise at least five recombinant immunogenic components. The immunogenic components can be MPT antigens or DNA polynucleotides encoding MPT antigens, or combinations thereof. MPT antigens used in the invention include MPT 85A, 85B, 85C, 35 kDa, super oxide dismutase (SOD), MptC, MptD and ESAT-6 protein. The method comprises administering the composition to an animal in an amount effective to stimulate an immunological response against MPT bacteria. The method is of benefit to any animal susceptible to MPT infection, but is particularly beneficial for ruminants.

Abstract: The invention provides novel immunogenic proteins LigA and LigB from Leptospira for use in the development of effective vaccines and antibodies, as well as improved diagnostic methods and kits.

Abstract: Embodiments of the invention provide a system and method for automatically managing a network port based on a calendar function. In one embodiment, a discovery protocol is provided for automatically discovering at least one port of at least one switch in a network. Furthermore, a management protocol is provided. The management protocol is configured to automatically manage the at least one port of the at least one switch in the network based on a programmable calendar function. In addition, a reconfiguration protocol is also provided. The reconfiguration protocol is configured to reconfigure the calendar function of the automatic management of the at least one port of the at least one switch in the network.

Abstract: Provided are compositions and methods for stimulating an immune response against Mycobacterium avium subspecies paratuberculosis (MAP). The compositions include a recombinant polypeptide that contains from its N-terminus to C-terminus a C-terminal fragment of MAP protein Map3527, a Map1519 protein amino acid sequence, followed by an N-terminal portion of Map3527. The method comprises administering the composition to an animal in an amount effective to stimulate an immunological response against MAP bacteria. The method is of benefit to any animal susceptible to MAP infection, but is particularly beneficial for ruminants.

Abstract: Embodiments of the invention provide a system and method for automatically managing a network port based on a calendar function. In one embodiment, a discovery protocol is provided for automatically discovering at least one port of at least one switch in a network. Furthermore, a management protocol is provided. The management protocol is configured to automatically manage the at least one port of the at least one switch in the network based on a programmable calendar function. In addition, a reconfiguration protocol is also provided. The reconfiguration protocol is configured to reconfigure the calendar function of the automatic management of the at least one port of the at least one switch in the network.

Abstract: This invention provides the sequence of 5,299 nucleotides from the E. canis genome. There are four proteins, ProA, ProB, MmpA, and a cytochrome oxidase homolog, as well as a partial lipoprotein signal peptidase homolog at the carboxy terminus, coded for in this cloned fragment. The antigenic properties of these proteins allow them to be used to create a vaccine. An embodiment of this invention includes the creation of a DNA vaccine, a recombinant vaccine, and a T cell epitope vaccine. Another embodiment of this invention includes the use of serological diagnosis techniques.